ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
RenovoRx Inc

RenovoRx Inc (RNXT)

1.33
0.01
(0.76%)
終了 1月11日 6:00AM
1.32
-0.01
(-0.75%)
取引時間後: 7:20AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
1.32
買値
1.28
売値
1.43
出来高
48,895
1.30 日の範囲 1.40
0.7736 52 週間の範囲 1.86
時価総額
前日終値
1.32
始値
1.40
最終取引時間
財務取引量
US$ 65,397
VWAP
1.3375
平均取引量 (3 か月)
72,241
発行済株式数
24,001,339
配当利回り
-
PER
-3.12
1 株当たり利益 (EPS)
-0.43
歳入
-
純利益
-10.23M

RenovoRx Inc について

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
RenovoRx Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker RNXT. The last closing price for RenovoRx was US$1.32. Over the last year, RenovoRx shares have traded in a share price range of US$ 0.7736 to US$ 1.86.

RenovoRx currently has 24,001,339 shares in issue. The market capitalisation of RenovoRx is US$31.68 million. RenovoRx has a price to earnings ratio (PE ratio) of -3.12.

RNXT 最新ニュース

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Two additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025 The accepted abstracts support RenovoRx’s novel Trans-Arterial...

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial Plans in 2025 New Patent Filing Anticipated to...

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI...

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates Initial Target Market Size for RenovoCath...

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical...

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.06-4.347826086961.381.451.32488011.36481235CS
4001.321.471.1637861.27919732CS
120.2928.15533980581.031.580.7736722411.25689787CS
260.086.451612903231.241.580.7736499471.20300362CS
52-0.01-0.7518796992481.331.860.7736485021.23877201CS
156-2.71-67.24565756824.035.7450.5306922172.27830863CS
260-6.93-848.2516.740.53063800977.55672096CS

RNXT - Frequently Asked Questions (FAQ)

What is the current RenovoRx share price?
The current share price of RenovoRx is US$ 1.32
How many RenovoRx shares are in issue?
RenovoRx has 24,001,339 shares in issue
What is the market cap of RenovoRx?
The market capitalisation of RenovoRx is USD 31.68M
What is the 1 year trading range for RenovoRx share price?
RenovoRx has traded in the range of US$ 0.7736 to US$ 1.86 during the past year
What is the PE ratio of RenovoRx?
The price to earnings ratio of RenovoRx is -3.12
What is the reporting currency for RenovoRx?
RenovoRx reports financial results in USD
What is the latest annual profit for RenovoRx?
The latest annual profit of RenovoRx is USD -10.23M
What is the registered address of RenovoRx?
The registered address for RenovoRx is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the RenovoRx website address?
The website address for RenovoRx is www.renovorx.com
Which industry sector does RenovoRx operate in?
RenovoRx operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.7M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.69M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.56M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.16B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.45M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

RNXT Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock